Reporting by Rob Curran
Development-stage biopharmaceutical company Otonomy Inc. shares said a drug candidate showed promise in a mid-stage trial involving patients with hearing loss.
Patients participating in the Phase 2a clinical trial of the OTO-413 drug exhibited significant improvement in hearing tests compared with the control group, the San Diego company said.
The OTO-413 injection was tested on....
Read the original article on MarketWatch here.
Comments